Abstract
In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this setting and further research on overall survival benefit is needed to prove drug efficacy.
Original language | English (US) |
---|---|
Pages (from-to) | 736-738 |
Number of pages | 3 |
Journal | Trends in Cancer |
Volume | 6 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2020 |
Keywords
- FDA
- immunotherapy
- small cell lung cancer
- surrogate endpoints
ASJC Scopus subject areas
- Oncology
- Cancer Research